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Abstract 
 
Clear cell renal cell carcinoma (ccRCC) is the most common subtype of all kidney tumors. 
During the last few years, epigenetics has emerged as an important mechanism in ccRCC 
pathogenesis. Recent reports, involving large-scale methylation and sequencing analyses, 
have identified genes frequently inactivated by promoter methylation and recurrent 
mutations in genes encoding chromatin regulatory proteins. Interestingly, three of detected 
genes (PBRM1, SETD2 and BAP1) are located on chromosome 3p, near the VHL gene, 
inactivated in over 80% ccRCC cases. This suggests that 3p alterations are an essential part 
of ccRCC pathogenesis. Moreover, most of the proteins encoded by these genes cooperate in 
histone H3 modifications. The aim of this review is to summarize the latest discoveries 
shedding light on deregulation of chromatin machinery in ccRCC. Newly described ccRCC-
specific epigenetic alterations could potentially serve as novel diagnostic and prognostic 
biomarkers and become an object of novel therapeutic strategies. 
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Introduction 
 
Kidney cancer is one of the 15 most 
common malignancies occurring globally, 
with more than 270,000 new cases every 
year worldwide (1-3). The majority of 
malignant kidney tumors are renal cell 
carcinomas (RCC) with the most common 
and aggressive subtype being clear-cell 
renal cell carcinoma (ccRCC), comprising 
approximately 70% of all kidney tumors (4). 
Localized ccRCC is potentially curable by 
resection, though about 30% of patients 
relapse after initial nephrectomy (5). 
Unfortunately, ccRCC is frequently non-
symptomatic in the early phases, and is 
repeatedly detected in advanced stage often 
with metastases (6). When metastasized, 
ccRCC is chemo- and radiation-resistant 
and in most cases remains incurable, 
resulting in a 95% mortality rate (7, 8).  
 
To date no effective ccRCC treatment has 
been developed and none of the potential 
biomarkers have been approved for clinical 
application. For many years von Hippel-
Lindau (VHL) tumor suppressor gene (TSG) 
was the only TSG associated with ccRCC 
pathogenesis (9). Attempts to detect other 
mutated genes have been unsuccessful for 
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a long time, though deregulation of 
chromatin machinery has recently emerged 
as an important mechanism in renal 
neoplasms. Large-scale sequencing projects 
have identified novel TSGs, mapped to the 
frequently lost 3p21 locus and functioning 
as epigenetic chromatin and/or histone 
modifiers, indicating epigenetic changes 
may play an important role in ccRCC 
development (10-12). Silencing of VHL 
through promoter methylation in ccRCC 
was one of the first examples of this 
phenomenon and so far approximately 60 
genes have been suggested to be 
epigenetically deregulated in ccRCC (13). 
Here, we summarize the most recent 
discoveries in the field of ccRCC 
epigenomics, providing potential diagnostic 
and prognostic biomarkers as well as 
possible novel targets for therapeutic 
intervention. 
 
Epigenetic alterations in ccRCC 
 
The main mechanisms responsible for 
chromatin state regulation are: DNA 
methylation, nucleosome remodeling, and 
covalent histone modifications through 
methylation, acetylation, phosphorylation, 
ubiquitination, or sumoylation. These 
modifications can directly change DNA 
organization and/or accessibility as well as 
lead to the recruitment of proteins altering 
chromatin structure and in consequence 
influence transcription, replication, 
recombination and DNA repair (14, 15). 
Recent genome-wide methylation studies 
and sequencing projects demonstrated that 
the disruption of epigenetic control has a 
significant role in the initiation and 
progression of ccRCC (16-18). 
 
Inactivation of potential tumor suppressor 
genes through DNA methylation 
 
DNA methylation is the best studied 
epigenetic modification and the only 
epigenetic mark with a well described 
mechanism of mitotic inheritance (19). It 
plays an important role in various 
biological processes, for example, genomic 
imprinting, transposable elements 
silencing, and embryonic development (20). 
Methylation patterns are generated and 
maintained by DNA methyltransferases 
(DNMTs). DNMT1 acts during replication 
and maintains methylation of the new DNA 
strand, DNMT3a and DNMT3b are de novo 
methyltransferases that act independently 
of replication and display no preference for 
unmethylated nor hemi-methylated DNA 
(20-23).  
 
The majority of CpG-rich promoter regions 
(CpG islands) occupying near 60% of 
human gene promoters usually remain 
unmethylated (24). Gene silencing by 
promoter region methylation of TSGs is a 
frequent mechanism described in human 
cancers, with epigenetic inactivation of VHL 
in ccRCC being one of the first examples 
(13, 25, 26). VHL, while mutated in 
approximately 80% of sporadic ccRCC, is 
inactivated by methylation in an additional 
~10% of cases (27, 28). Identification of 
other epigenetically inactivated TSGs was 
an important approach to study the 
pathogenesis of ccRCC, and promoter 
hypermethylation of several genes 
commonly inactivated in ccRCC has been 
documented (18). Based on a search of 
online databases, compilation of candidate 
genes reported in numerous studies to 
show tumor-specific hypermethylation in 
ccRCC, has been published in 2010 (28). 
Morris et al. described 38 genes methylated 
in ccRCC, among those only a small 
number was methylated with high 
frequency (≥50% of cases: APAF1, COL1A1, 
DKK2, DKK3, SFRP2, SFRP4, SFRP5, and 
WIF1) while rarely (<10%) in matched 
normal tissue (28).  
 
The earlier, initial studies mostly 
implemented targeted, candidate-driven 
analyses. Recently, several whole genome 
strategies also have been applied. A large 
functional epigenetic screen of gene 
upregulation post 5-aza-2’-deoxycytidine 
demethylation treatment by high-density 
gene expression microarrays in 11 RCC cell 
lines (KTCL 26, RCC4, UMRC2, UMRC3, 
SKRC18, SKRC39, SKRC45, SKRC47, 
SKRC54, 786-0 and Caki-1) was applied by 
Morris et al. Genes re-expressed after 
demethylation were validated in 61 primary 
tumors (~80% clear cell and 20% non-clear 
cell RCC). Five genes (BNC1, COL14A1, 
CST6, PDLIM4, and SFRP1) demonstrated 
frequent tumor-specific promoter region 
methylation (>30%), associated with 
transcriptional silencing. Re-expression of 
BNC1, CST6, and SFRP1 suppressed the 
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growth of RCC cell lines, whereas RNAi 
knock-down of BNC1, SFRP1, and 
COL14A1 increased their growth, 
suggesting tumor suppressor activity (29). 
Similarly, methylated DNA 
immunoprecipitation (MeDIP) of primary 
tumors, followed by high-density whole-
genome expression microarray comparative 
analysis revealed 9 genes frequently 
methylated in primary ccRCC tumour 
samples: PCDH8 (58%), KLHL35 (39%), 
ATP5G2 (36%), CCDC8 (35%), FBN2 (34%), 
ZSCAN18 (32%), their promoter 
hypermethylation resulting in gene 
silencing (30). None of these genes have 
been reported previously to be methylated 
in RCC nor other cancers. 
 
Genome-wide DNA methylation studies in 
ccRCC have also been performed using 
BeadChip arrays. Comparison of  DNA 
methylation profiles in familial (n = 29) and 
sporadic (n = 20) VHL+/+ ccRCC showed 
more frequently methylated RASSF1, 
PITX2, CDH13, HS3ST2, TWIST1, TAL1, 
TUSC3, and DCC loci in sporadic cases, 
indicating differences in tumorigenesis 
mechanisms dependent on VHL status (31). 
Several novel ccRCC TSG candidates 
(SLC34A2, OVOL1, DLEC1, TMPRSS2, 
SSTand BMP4) have been found in a global 
study of CpG methylation in 38 ccRCC and 
9 age-matched healthy tissues (~27,500 
CpGs and >14,000 genes) (32). All of those 
exhibited frequent transcriptional silencing 
associated with promoter methylation (20-
60% of cases).  
 
Dmitriev et al. focused on genetic and 
epigenetic destabilization of genes on 
chromosome 3 (33). The study (validated by 
bisulfite genomic sequencing) showed 22 
genes displaying high frequency of 
methylation (17–57%) and/or deletion in 
ccRCC. Identified genes included well-
known TSGs VHL, CTDSPL, LRRC3B, 
ALDH1L1, and EPHB1, but also genes not 
previously linked to cancer development 
(LRRN1, GORASP1, FGD5, and PLCL2). 
Proteins encoded by a part of these genes 
are involved in signaling pathways and 
biological processes frequently affected in 
cancer, like apoptosis (GORASP1), 
regulation of actin cytoskeleton (FGD5), 
transmembrane signaling systems (GNAI2) 
or regulation of NFkappaB activity 
(NKIRAS1). Dmitriev et al. further confirm 
that mechanism of ccRCC development is 
linked to destabilization of genes at 
chromosome 3, discussed in more detail in 
the next paragraph. 
 
Studies described above have identified a 
large number of genes methylated in 
sporadic ccRCC. There is small overlap 
between studies and consensus on which 
genes play a role in its etiology and 
whether any of those are of relevance 
clinically. However, all of the reported 
genes are involved in processes often 
deregulated during tumorigenesis: 
apoptosis, proliferation, cell survival and 
tumor invasion.  The Cancer Genome Axis 
(TCGA) Kidney Renal Clear Cell Carcinoma 
(KIRC) database provides an excellent 
opportunity to confirm and unify previously 
obtained results (16). These data include 
199 ccRCC tumor/normal paired analyses 
using the Infinium HumanMethylation27 
BeadChip validated on 160 ccRCC 
tumor/normal paired samples using the 
Infinium HumanMethylation450 BeadChip.   
 
Mutations of genes regulating epigenetic 
modifications 
 
Non-covalent mechanisms, such as 
nucleosome remodeling can change 
chromatin structure and influence gene 
activity by altering the accessibility of 
regulatory DNA sequences to transcription 
factors (34). Currently, there are four 
known families of ATP-dependent 
remodeling complexes, characterized by 
different core ATPases: SWI/SNF, ISWI, 
NURD/Mi-2/CHD and INO80. Mutations of 
SWI/SNF subunits were documented in 
approximately 20% of human cancers (for 
example, medulloblastoma, breast cancer), 
indicating that inactivation of this complex 
is important in tumor formation (35). 
PBRM1 encodes the chromatin targeting 
subunit (BAF180) of the ATP-dependent 
SWI/SNF chromatin remodeling complex, 
implicated in proliferation, replication, 
transcription and DNA repair (Figure 1) 
(36). Truncating mutations in PBRM1 have 
been found in 88/257 (34%) of ccRCC 
cases (10). Further studies have shown 
similar mutation frequencies, making it the 
second most commonly altered gene in 
ccRCC, next to VHL (37). However, there is 
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Figure 1. Schematic representation of epigenetic changes identified in ccRCC tumors. DNMTs - DNA 
methyltransferases; HDMs - histone demethylases; HMTs - histone methyltransferases; Hubs - 
histone ubiquitinases; HDUbs - histone deubiquitinases; SWI/SNF - chromatin remodeling complex. 
 
 
no significant correlation between lack of 
PBRM1 expression and VHL mutations, 
and PBRM1 mutations occur at similar 
rates in tumors with or without VHL 
mutations (38). Functional in vitro assays 
in ccRCC cell lines with PBRM1 silenced 
via siRNA resulted in a significant increase 
of proliferation in ACHN and 786-O cell 
lines (with wild type PBRM1) but not in 
A704 with a homozygous PBRM1 
truncating mutation (10). In turn, 
reintroduction of PBRM1 into cells induced 
the cyclin-dependent kinase inhibitor p21 
expression and led to reduction in cell 
proliferation (39). PBRM1 silencing results 
also in increased colony formation in soft 
agar and increases cell migration in 786-O, 
SN12C and TK10 cells, suggesting a tumor 
suppressive role for PBRM1 in ccRCC (10). 
Additionally, ccRCCs deficient in PBRM1 
are associated with a distinct gene-
expression signature enriched for genes 
implicated in the cytoskeleton and cell 
motility (40). However, how loss of PBRM1 
function affects chromatin modulation 
patterns and promotes tumorigenesis is 
unknown. 
 
In a small proportion of ccRCCs, ARID1A 
(1p35) encoding for different subunit of the 
SWI/SNF complex (BAF250A) was also 
found to be mutated (Figure 1) (10). In 
another study, in 16% patients with 
ccRCC, ARID1A copy number loss was 
detected - 67% of tumors (n=79) had 
significantly lower expression of BAF250A 
than control tissue, and in approximately 
70% (n=404) decreased ARID1A mRNA 
expression was found (41, 42). ARID1A 
mutations are present at high frequency in 
other cancers, for example, ovarian clear 
cell carcinomas (50%), ovarian 
endometrioid carcinomas (30%), and 
gastric cancers (29%), and studies have 
suggested its roles in proliferation, 
differentiation, and apoptosis (43). The 
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mechanism of ARID1A alterations and their 
role in ccRCC pathogenesis is still unclear. 
 
Besides chromatin remodeling, histone 
modifications, controlled by balanced 
activity of histone modifying enzymes, also 
play a critical role in maintaining the 
proper functioning of cells (44). Most 
common N-terminal tail modifications 
include acetylation and methylation of 
lysine or arginine and serine 
phosphorylation (45). Depending on their 
type and location, modifications may 
influence the accessibility of chromatin or 
can recruit and/or block non-histone 
effector proteins. Various enzymes are 
responsible for this dynamic regulation, for 
example, histone acetyltransferases (HATs) 
and methyltransferases (HMTs) that add 
acetyl and methyl groups, respectively, as 
well as enzymes removing these groups: 
histone deacethylases (HDACs) and 
demethylases (HDMs) (46). Altered 
expression of some of those have been 
discovered in ccRCC, including SETD2 and 
MLL2 (methyltransferases) as well as 
JARID1C/KDM5C and UTX/KDM6A 
(demethylases) (Figure 1).  
 
SETD2 (SET domain containing protein 2) 
is mutated in approximately 3% to 8% of 
ccRCC and its inactivation leads to loss or 
decrease of trimethylation of lysine 36 of 
histone H3 (H3K36me3) (10, 11, 47). In 
addition, a connection has been reported 
between SETD2 mutations and extensive 
DNA hypomethylation in ccRCC (16). 
Similar to VHL and PBRM1, SETD2 is 
located on chromosome 3p and it was 
proposed as a novel TSG in ccRCC. A meta-
analysis based on 5 different studies 
suggests SETD2 mutations cooperate with 
mutations in PBRM1 (48). In addition, 
Garlinger et al. have shown that distinct 
SETD2 mutations are present in the same 
tumor, suggesting a high selective pressure 
to mutate SETD2 (49). How its biallelic 
inactivation is connected to ccRCC remains 
unclear. Two studies have linked SETD2 
and H3K36me3 to DNA mismatch repair 
and microsatellite instability of tumors (50, 
51). This finding was not confirmed by 
Kanu et al., who suggest a role for SETD2 
in nucleosome reassembly, suppression of 
replication stress, and the coordination of 
DNA double-strand breaks (DSBs) repair by 
homologous recombination (HR) (52). 
Findings linking SETD2 to HR have been 
also reported by Carvalho et al., who 
showed it is required for ATM activation 
upon formation of DSBs, and for HR repair 
of DSBs by promoting the formation of 
RAD51 filaments. SETD2-mutant ccRCC 
cells displayed impaired DNA damage 
signaling, decreased cell survival after DNA 
damage and failure to activate the p53-
mediated checkpoint (53). Another 
methyltransferase frequently mutated in 
ccRCC, MLL2 (mixed-lineage leukemia 
protein 2, localized at 12q13.12), directs 
tri-methylation of histone H3 lysine 4 (11). 
The role of MLL2 in pathogenesis of ccRCC 
is currently unknown. 
 
TSG function was also suggested for 
UTX/KDM6A gene coding for histone 
demethylase (with 3% mutation frequency 
in ccRCC) (11, 54). UTX/KDM6A 
demethylates H3K27me3 linked with 
repressed chromatin. It associates with 
MLL2 which also interacts with another 
H3K4 demethylase JARID1C/KDM5C, 
found to be frequently deactivated in 
ccRCC. Loss of JARID1C in 786-O ccRCC 
cells (VHL -/-) leads to significantly lower 
H3K4Me3 levels than in VHL+/+. JARID1C 
is proposed to have a tumor suppressor 
role - its knockdown in 786-O VHL-/- ccRCC 
cells significantly enhanced tumor growth 
in a mice xenograft model (55). Taken 
together, these data implicate deregulation 
of methylation/demethylation of histone 
H3 (a major regulator of 
euchromatin/transcription), as an 
important and complex phenomenon in 
ccRCC etiology. 
 
The BRCA1 Associated Protein-1 (BAP1) 
gene is also often mutated in ccRCC (8–
14%) (12, 37, 56). It is located at 3p and 
codes for a nuclear deubiquitinase 
targeting H2A, one of the most abundant 
ubiquitinated proteins in the nucleus, next 
to H2B (Figure 1) (57). BAP1 interacts with 
Host Cell Factor C1 (HCF-1), which recruits 
histone-modifying enzymes and serves as a 
scaffold for chromatin remodeling 
complexes, promoting the inhibition of cell 
proliferation (37). Interestingly, BAP1 and 
PBRM1 mutations are mutually exclusive 
and loss of either BAP1 or PBRM1 proteins 
has been observed in approximately 70% of 
ccRCC cases (37, 56). Moreover, VHL-
deficient mice with one active allele of BAP1 
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exhibited features of human ccRCC, which 
suggests an important role of BAP1 in the 
pathogenesis of ccRCC (58). 
 
Chromatin organization and chromatin 
accessibility changes 
 
Formaldehyde-assisted isolation of 
regulatory elements (FAIRE), enables 
interrogation of chromatin accessibility 
changes and is based on isolation of 
nucleosome-depleted regions of DNA, 
harboring regulatory elements (active 
transcriptional start sites, transcriptional 
enhancers, and silencers). Studies using 
this method showed functional 
consequences of mutations in genes 
encoding chromatin regulatory proteins on 
chromatin organization and transcription 
in human tumors (59). Buck et al. 
performed FAIRE on matched pairs of 
tumor/healthy samples and identified 
decreased chromatin accessibility at genes 
previously associated with ccRCC, such as 
PBRM1, SETD2 and MLL2 (60). Array-
based methylation analysis on this same 
set of tumors revealed that chromatin 
remodeling can occur in parallel with 
methylation or independent of it. Recently, 
Simon et al. used FAIRE to define the 
chromatin landscape in a cohort of 42 
primary ccRCC tumors and 7 matched 
normal tissues, and studied the  possible 
association of variations in chromatin 
organization with mutations in SETD2 (61). 
Changes in chromatin accessibility were 
identified primarily within actively 
transcribed genes, and increase in 
chromatin accessibility was linked to 
alterations in RNA processing (for example, 
intron retention and aberrant splicing), 
affecting ~25% of all expressed genes. 
Moreover, in tumors lacking H3K36me3 
decreased nucleosome occupancy proximal 
to aberrantly spliced exons was observed. 
This study links mutations in SETD2 to 
chromatin accessibility changes and RNA 
processing defects.  
 
Epigenetic modifications as markers for 
ccRCC diagnosis, prognosis, and 
surveillance 
 
No effective and noninvasive strategy for 
detection and prognosis of ccRCC has been 
established to date. ccRCC usually remains 
asymptomatic until a relatively late stage, 
therefore early detection, accurate 
prediction of disease progression and 
monitoring are critical. Potentially, altered 
expression of recently reported histone 
modifiers, might be of clinical relevance 
(Table 1). ccRCC patients with BAP1 
mutations were significantly more likely to 
present with advanced clinical stage and 
metastases, and shorter overall survival 
(56, 62). Similarly, PBRM1 downregulation 
correlated with advanced tumor stage, low 
differentiation grade and worse patient 
outcome while SETD2 mutations correlated 
with a high relapse rate (38, 56). Moreover, 
tumors with expression changes of PBRM1 
or BAP1, SETD2 and KDM5C were more 
likely to present with stage III disease or 
higher (62). Analysis of cancer specific 
survival (CSS) performed in a large patient 
cohort of 188 patients and additionally 421 
from TCGA, partially confirmed these initial 
findings (63). BAP1 mutations were 
associated with worse CSS in both cohorts 
(MSKCC, p=0.002; TCGA, p=0.002) while 
SETD2 only in the TCGA cohort (p=0.036). 
PBRM1 mutations were not correlated with 
CSS in this study. 
 
Cancer cells display global alterations of 
DNA methylation, therefore methylation 
profiling may be implemented in ccRCC 
biomarker discovery. A specific cancer 
phenotype designated as the CpG island 
methylator phenotype (CIMP) was found in 
ccRCC. It is characterized by DNA 
hypermethylation of 17 marker genes and 
by more aggressive tumors, poorer patient 
outcome, and a higher probability of both, 
recurrence and disease-related death. 
ccRCC-CIMP was validated and could be 
useful for diagnosis and prognostication of 
the patients (64, 65). A vast amount of 
aberrantly methylated genes, described in 
previous paragraphs and exemplified in 
Table 1, may potentially serve as 
biomarkers (4, 18, 66, 67). However, to 
predict methylation specificity/sensitivity 
and thus diagnostic potential, these data 
require more detailed investigation. 
 
Most studies on both mutation status of 
histone modifiers and gene methylation 
were conducted on tissue samples. Fluid 
based biomarkers for detection, staging 
and progression monitoring would be more 
attractive due to easy, non-invasive 
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Table 1. Genes involved in epigenetic DNA and chromatin modifications, proposed as 
potential biomarkers in ccRCC (a genes with methylation frequency above 30%).  
 Gene function Gene 
name 
Locus Methylation
/ 
mutation 
frequency 
Type of 
sample 
Clinical utility Type of 
potential 
biomarker 
Ref. 
P
ro
m
o
te
r 
m
e
th
y
la
ti
o
n
 a
 
 
W
n
t/
b
e
ta
-c
a
te
n
in
 s
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n
a
l 
tr
a
n
s
d
u
c
ti
o
n
 p
a
th
w
a
y
 
  
N
e
g
a
ti
v
e
 
re
g
u
la
ti
o
n
 
DKK1 10q11 52% tumor 
(n=50) 
methylation frequency higher 
in advanced tumor stage 
prognostic (89) 
DKK2 
 
4q25 
 
58% tumor 
(n=52) 
 
methylation frequency higher 
in high grade, stage, and size 
tumors 
prognostic 
 
(90) 
DKK3 11p15 50% tumor 
(n=62) 
cancer cell specific 
methylation 
predictive (91) 
 
P
o
s
it
iv
e
 r
e
g
u
la
ti
o
n
 
 
SFRP1  
 
8p11 34% 
 
 
tumor 
(n=61) 
 
methylation associated with 
poor prognosis  
prognostic 
 
 
(27) 
SFRP2  
 
4q31 
 
 
 
53% 
 
 
48% 
 
tumor 
(n=62) 
 
serum 
(n=33) 
cancer cell specific 
methylation 
 
methylation frequency higher 
in high grade and stage 
tumors  
predictive 
 
 
prognostic 
 
(91) 
SFRP4  
 
7p14-13 
 
53 % 
 
tumor 
(n=62) 
cancer cell specific 
methylation 
predictive 
prognostic 
(91) 
SFRP5  
 
10q24 
 
 
56% 
 
 
45% 
 
tumor 
(n=62) 
 
serum 
(n=33) 
cancer cell specific 
methylation 
 
methylation frequency higher 
in high grade and stage 
tumors 
predictive 
 
 
prognostic 
(91) 
WIF1 
 
12q14 73% tumor 
(n=62) 
cancer cell specific 
methylation 
predictive (91) 
A
p
o
p
to
ti
c
 s
ig
n
a
li
n
g
 
p
a
th
w
a
y
 
  
  
  
  
  
  
P
ro
-a
p
o
p
to
ti
c
 
APAF-1  
 
12q23 
 
 
41% 
 
41% 
tumor 
(n=90) 
tumor 
(n=196) 
methylation associated with 
low overall survival 
risk of metastatic disease, 
cancer-related death  
prognostic 
 
prognostic 
 
(92) 
 
(93) 
DAPK-1 
 
9q21 
 
64% 
 
tumor 
(n=196) 
frequently methylated in high 
stage tumors 
prognostic 
 
(93) 
 KILLIN 10q23 95% tumor 
(n=20) 
cancer cell specific 
methylation 
diagnostic (68) 
Extracellular 
matrix 
structural 
constituent 
COL1A1  
 
17q21  
 
65% tumor 
(n=20) 
frequently methylated in 
early-stage tumors 
prognostic 
 
(94) 
COL14A1 8q23  44% tumor 
(n=41) 
poor prognosis independent 
of tumor size, stage or grade 
prognostic (27) 
FBN2 5q23 40% 
 
52% 
tumor 
(n=199) 
(n=160) 
cancer cell specific 
methylation 
 
predictive 
 
(95) 
Regulation of 
transcription 
BNC1 15q25 
 
46% 
 
tumor 
(n=61) 
poor prognosis independent 
of tumor size, stage or grade 
prognostic 
 
(27) 
HOXA5 7p15 51% tumor 
(n=62) 
methylation frequency higher 
in high Fuhrman grade 
tumors 
prognostic (96) 
TSG DLEC1 3p21 31% tumor 
(n=81) 
methylation frequency higher 
in more advanced stage 
tumors  
prognostic (97) 
Inhibitor of 
 
GREM1 15q12 63% tumor 
(n=147) 
high methylation frequency 
associated with increased 
tumor size, grade and stage 
prognostic 
 
 
(98) 
C
h
ro
m
a
ti
n
 m
o
d
if
ie
rs
 m
u
ta
ti
o
n
s
 
SWI/SNF 
chromatin 
remodeling 
complex 
PBRM1 3p21 29% tumor 
(n=185) 
mutations associated with 
advanced tumor stage 
prognostic (61) 
histone H3K4 
demethylation 
JARID1C/ 
KDM5C 
Xp11 8% tumor 
(n=185) 
mutations associated with 
advanced tumor stage 
prognostic (61) 
histone H3K36 
trimethylation 
SETD2 3p21 8% 
 
11% 
11% 
tumor 
(n=185) 
(n=421) 
(n=106) 
mutations associated with  
 
worse cancer-specific survival 
high relapse rate 
prognostic 
 
prognostic 
prognostic 
(61) 
 
(62) 
(55) 
catalytic 
subunit of  the 
histone H2A 
deubiquitinase 
BAP1 3p21 11% 
 
 
6% 
 
6% 
10% 
tumor 
(n=132) 
 
(n=185) 
 
(n=188) 
(n=421) 
mutations associated with 
metastases and advanced 
tumor stage  
higher stage & grade tumors; 
shorter overall survival 
worse cancer-specific survival 
prognostic 
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prognostic 
(99) 
 
 
(61) 
 
(62) 
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acquisition. Nevertheless, to date only a 
limited number of studies aimed at finding 
specific ccRCC biomarkers in blood or 
urine has been executed. Methylation-
based biomarker candidates found in urine 
and serum of ccRCC patients, for example,  
INK4, SFRP1, and SFRP2 were reviewed by 
Baldewijns et al. in 2008 (4). Recently, to 
our knowledge, only two more reports have 
been published. RASSF1A, and VHL 
(detected in serum) as well as KILLIN, and 
LINE-1 (detected in peripheral blood) have 
been proposed as predictive biomarkers 
(68-70). Their association with ccRCC is 
suggested by significantly higher levels of 
promoter hypermethylation in ccRCC 
patients than in patients with benign 
tumors and healthy controls, respectively. 
High throughput screening strategies that 
revealed many new ccRCC biomarker 
candidates, give hope that in the near 
future exploration of fluid based epigenetic 
biomarkers will be intensified. 
 
Epigenetic therapies 
 
Studies that highlighted importance of 
epigenetic modifications in the 
pathogenesis of ccRCC provided new 
potential objects for therapeutic 
intervention. Cancer cells, including 
ccRCC, are generally characterized by the 
overexpression of HDACs leading to 
decreased histone acetylation and 
consequently silencing of genes involved in 
the regulation of key cancer pathways (71, 
72). Several studies proved the efficacy of 
some HDAC inhibitors in reducing tumor 
growth in cancer patients in phase I and II 
clinical trials (72-74). Currently, HDACs 
are intensively explored as targets of ccRCC 
therapy (67, 75). Monotherapies such as, 
with panobinostat, did not bring 
satisfactory results to date. A phase II 
study enrolled 20 patients with metastatic 
refractory ccRCC, previously treated with 
mTOR inhibitor(s). In the first evaluation, 
five patients showed stable disease and 
three patients experienced progression. 
Treatment was generally well tolerated but 
the median progression-free survival was 
limited to 17 months. Hence, panobinostat 
is recommended only in combination with 
other anticancer drugs (76). Also 
depsipeptide, tested in 29 patients with 
metastatic RCC (ccRCC n=25) in a phase II 
study, did not show satisfactory results as 
a monotherapy. The overall treatment 
response rate was 7%, in addition severe 
side effects like fatigue, nausea, vomiting, 
anemia were observed (77). 
 
Combined treatment approaches with 
HDAC inhibitors seem to be more effective 
than monotherapy. In models of RCC, the 
HDAC inhibitor vorinostat improved the 
anticancer activity of temsirolimus (78). 
Reduced cell viability, clonogenic survival 
and increased cell death was observed in 
RCC cell lines (86-O, A498, 769-P, Caki-1, 
Caki-2, SW839, ACHN, G401 and SK-NEP-
1) in response to combined treatment. In 
xenografts of RCC cell lines (786-O and 
Caki-1), vorinostat inhibited tumor cell 
proliferation, induced apoptosis and 
impaired angiogenesis, through a decrease 
in HIF-2a expression and vessel density. In 
vitro and in vivo studies have also shown 
that a combination of retinoic acid and 
HDAC inhibitor trichostatin A is more 
efficient than each drug alone (79). The 
combined therapy enhanced the retinoic 
acid pathway signaling, leading to a 
reduction of proliferation of human RCC 
cells lines (SK-RC-39 and SK-RC-45), 
inhibition of tumor model growth (SK-RC-
39) and increased apoptosis. In 
combination with retinoids, also MS-275, a 
benzamine derivative HDAC inhibitor, 
showed a better inhibitory effect on tumor 
growth in vivo. This effect persisted after 
treatment withdrawal, and after 
continuous treatment in animals RCC1.18 
tumor progression was not observed (80). 
Interestingly, an induction of retinoic acid 
receptor beta was observed during 
treatment, suggesting HDAC inhibitors 
might revert retinoid resistance. 
 
There are also attempts to develop drugs 
selectively targeting other enzymes involved 
in epigenetic modulation, especially histone 
methyltransferases or histone 
demethylases. There are a few 
methyltransferase inhibitors showing 
promising results in cancer models (75, 
81). In ccRCC, the S‑adenosylhomocysteine 
hydrolase inhibitor, 3‑deazaneplanocin A 
(DZNep), depletes cellular levels of the 
enhancer of zeste homologue 2 (EZH2). 
EZH2 is a catalytic subunit of the 
polycomb repressive complex 2 (PRC2), a 
histone methyltransferase that catalyzes 
tri-methylation of lysine 27 on histone 3 
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(82). DZNep reduces H3K27 trimethylation 
levels, additionally, RCC cells exposed to 
DZNep showed a significant decrease of cell 
migration and invasion in vitro, as well as 
inhibition of tumor growth, and prolonged 
survival in the in vivo mice model.  
 
In a recent report published by Adelaiye et 
al., resistance to sunitinib was studied in 
mice bearing two different patient-derived 
ccRCC xenografts (83). Increasing the drug 
dose led to partial overcome of initial 
sunitinib-induced resistance, suggesting its 
association with epigenetic changes such 
as overexpression of the methyltransferase 
EZH2 and modulation of histone marks. 
Moreover, specific EZH2 inhibition resulted 
in increased in vitro anti-tumor effect of 
sunitinib. These promising results indicate 
that high throughput screening strategies 
could be used to identify further drug-
candidates.  
 
Perspectives 
 
Availability of high-throughput methods 
have facilitated investigation of epigenetic 
modifications in general. The Roadmap 
Epigenomics Program recently published 
mapped epigenomes of 111 types of 
primary human healthy cells and tissues, 
providing valuable reference epigenome 
maps (84), moreover many epigenome-wide 
association studies (EWASs) initiated in 
various diseases are currently intensively 
conducted (85). Epigenetic studies have 
also widely broadened our understanding 
of the biology of ccRCC, providing evidence 
of various DNA mutation and methylation 
events, chromatin alterations and changes 
of DNA accessibility, and altogether 
suggesting that epigenetic alterations are 
connected to ccRCC 
pathogenesis/progression and require 
further detailed examination. A number of 
new large-scale projects seeking RCC 
biomarkers are currently ongoing, for 
example, CAGEKID, “Biomarker pipeline” 
(NIH), EuroTARGET or the PREDICT 
consortium (66, 86-89). These studies are 
expected to identify and characterize novel 
candidate biomarkers for ccRCC detection, 
staging and monitoring. 
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